Show simple item record

Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau

dc.contributor.authorBrendel, Matthias
dc.contributor.authorDeussing, Maximilian
dc.contributor.authorBlume, Tanja
dc.contributor.authorKaiser, Lena
dc.contributor.authorProbst, Federico
dc.contributor.authorOverhoff, Felix
dc.contributor.authorPeters, Finn
dc.contributor.authorvon Ungern-Sternberg, Barbara
dc.contributor.authorRyazanov, Sergey
dc.contributor.authorLeonov, Andrei
dc.contributor.authorGriesinger, Christian
dc.contributor.authorZwergal, Andreas
dc.contributor.authorLevin, Johannes
dc.contributor.authorBartenstein, Peter
dc.contributor.authorYakushev, Igor
dc.contributor.authorCumming, Paul
dc.contributor.authorBoening, Guido
dc.contributor.authorZiegler, Sibylle
dc.contributor.authorHerms, Jochen
dc.contributor.authorGiese, Armin
dc.contributor.authorRominger, Axel
dc.description.abstractAbstract Background Augmenting the brain clearance of toxic oligomers with small molecule modulators constitutes a promising therapeutic concept against tau deposition. However, there has been no test of this concept in animal models of Alzheimer’s disease (AD) with initiation at a late disease stage. Thus, we aimed to investigate the effects of interventional late-stage Anle138b treatment, which previously indicated great potential to inhibit oligomer accumulation by binding of pathological aggregates, on the metabolic decline in transgenic mice with established tauopathy in a longitudinal 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) study. Methods Twelve transgenic mice expressing all six human tau isoforms (hTau) and ten controls were imaged by FDG-PET at baseline (14.5 months), followed by randomization into Anle138b treatment and vehicle groups for 3 months. FDG-PET was repeated after treatment for 3 months, and brains were analyzed by tau immunohistochemistry. Longitudinal changes of glucose metabolism were compared between study groups, and the end point tau load was correlated with individual FDG-PET findings. Results Tau pathology was significantly ameliorated by late-stage Anle138b treatment when compared to vehicle (frontal cortex − 53%, p < 0.001; hippocampus − 59%, p < 0.005). FDG-PET revealed a reversal of metabolic decline during Anle138b treatment, whereas the vehicle group showed ongoing deterioration. End point glucose metabolism in the brain of hTau mice had a strong correlation with tau deposition measured by immunohistochemistry (R = 0.92, p < 0.001). Conclusion Late-stage oligomer modulation effectively ameliorated tau pathology in hTau mice and rescued metabolic function. Molecular imaging by FDG-PET can serve for monitoring effects of Anle138b treatment.
dc.publisherBioMed Central
dc.identifier.bibliographicCitationAlzheimer's Research & Therapy. 2019 Aug 01;11(1):67
dc.titleLate-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau
dc.rights.holderThe Author(s).
dc.bibliographicCitation.journalAlzheimer's Research & Therapy

Files in this item


This item appears in the following Collection(s)

Show simple item record